ESMO 2024 | DESTINY-Breast06: determining HER2-(ultra)low status in HR+ mBC

Giuseppe Viale • 15 Sep 2024

ESMO 2024

DESTINY-Breast06

Giuseppe Viale, MD, FRCPath, University of Milan, Milan, Italy, discusses updated findings from the Phase III DESTINY-Breast06 trial (NCT04494425) of trastuzumab deruxtecan (T-DXd) in patients with HR+, HER2-low, or HER2-ultralow metastatic breast cancer (mBC), who had previously received endocrine therapy but no chemotherapy. T-DXd significantly improved progression-free survival (PFS) compared to treatment of physician’s choice (TPC), with consistent benefits across HER2-low and HER2-ultralow subgroups. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.